Don’t Get Caught Holding Either of These ETFs.DekaBank Deutsche Girozentrale Purchases 1,493 Shares of Ryder System, Inc.Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with 's FREE daily email newsletter. Want to see what other hedge funds are holding QDEL? Visit to get the latest 13F filings and insider trades for QuidelOrtho Co. Does the Zillow Stock Forecast Hint Toward a Turnaround?.Delta Air Lines Looks Ready To Take Off.Trinseo Gets A Downgrade But That Doesn’t Stop It From Advancing. ![]() Is Taiwan Semiconductor A Good Investment For 2023?.Get a free copy of the research report on QuidelOrtho (QDEL).The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health testing products to detect and monitor disease progression across a spectrum of therapeutic areas and specialized diagnostic solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. According to, the company has an average rating of “Hold” and an average target price of $102.00. Four equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. They set a “hold” rating for the company. Finally, started coverage on QuidelOrtho in a research note on Wednesday. UBS Group raised QuidelOrtho from a “sell” rating to a “neutral” rating and set a $86.00 target price for the company in a research note on Friday. They set a “neutral” rating for the company. started coverage on shares of QuidelOrtho in a research report on Friday, June 17th. They set a “neutral” rating and a $90.00 price objective for the company. Citigroup initiated coverage on shares of QuidelOrtho in a research report on Monday, September 19th. QDEL has been the subject of several recent analyst reports. will post 11.6 earnings per share for the current fiscal year. As a group, analysts forecast that QuidelOrtho Co. The firm had revenue of $613.40 million during the quarter, compared to analyst estimates of $572.53 million. QuidelOrtho had a net margin of 36.43% and a return on equity of 42.55%. The company reported $2.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.56 by ($1.45). QuidelOrtho ( NASDAQ:QDEL – Get Rating) last released its quarterly earnings data on Thursday, August 4th. Institutional investors own 87.20% of the company’s stock. now owns 274,567 shares of the company’s stock worth $27,752,000 after purchasing an additional 12,700 shares during the period. lifted its position in QuidelOrtho by 4.8% during the first quarter. Renaissance Technologies LLC bought a new stake in QuidelOrtho during the first quarter worth about $34,321,000. now owns 317,543 shares of the company’s stock worth $35,711,000 after purchasing an additional 20,034 shares during the period. Charles Schwab Investment Management Inc. lifted its position in QuidelOrtho by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 610,752 shares of the company’s stock worth $68,686,000 after purchasing an additional 100,810 shares during the period. ![]() Dimensional Fund Advisors LP lifted its position in QuidelOrtho by 19.8% during the first quarter. State Street Corp now owns 1,106,702 shares of the company’s stock valued at $124,460,000 after acquiring an additional 72,308 shares during the period. State Street Corp boosted its position in shares of QuidelOrtho by 7.0% in the first quarter. Cambridge Investment Research Advisors Inc.’s holdings in QuidelOrtho were worth $239,000 as of its most recent filing with the SEC.Ī number of other institutional investors also recently modified their holdings of the business. The fund owned 2,456 shares of the company’s stock after selling 685 shares during the period. ( NASDAQ:QDEL – Get Rating) by 21.8% in the second quarter, HoldingsChannel reports. ![]() Cambridge Investment Research Advisors Inc.
0 Comments
Leave a Reply. |